Evidence map›Paper›PMID 33194065›Full record

ArticleAmerican journal of translational research2020

Molecular diagnosis and clinical outcome of a lung cancer patient with

Dafu Yang, Xue Han, Dan Li, Saiqiong Cui, Sisi Liu, Xue Wu, Zhaoxia Dai

Open access · greenAbstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Dafu YangThe Second Department of Thoracic Medical Oncology, The Second Hospital of Dalian Medical University Dalian, Liaoning, China.
Xue HanDepartment of Research and Development, Nanjing Geneseeq Technology Inc. Nanjing, Jiangsu, China.
Dan LiThe Second Department of Thoracic Medical Oncology, The Second Hospital of Dalian Medical University Dalian, Liaoning, China.
Saiqiong CuiThe Second Department of Thoracic Medical Oncology, The Second Hospital of Dalian Medical University Dalian, Liaoning, China.
Sisi LiuDepartment of Research and Development, Nanjing Geneseeq Technology Inc. Nanjing, Jiangsu, China.
Xue WuTranslational Medicine Research Institute, Geneseeq Technology Inc. Toronto, Ontario, Canada.
Zhaoxia DaiThe Second Department of Thoracic Medical Oncology, The Second Hospital of Dalian Medical University Dalian, Liaoning, China.
Dalian Medical University · CNJiangsu Province Science and Technology Department · CNOntario Power Generation · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesLi-Fraumeni syndrome (LFS) is an autosomal dominant cancer predisposition, mostly caused by germline MATERIALS AND

methodsThe patient's lung tumor, lymph nodes, liquid biopsies and germline control sample at various disease stages were subjected to next-generation sequencing (NGS). The

resultsA rare

conclusionsOur study highlights the importance of NGS in discovering rare genetic alterations to guide treatment decision-making, and provides meaningful insight into the potential treatment options for LFS patients with

Indexed as

EGFR-KDDLi-Fraumeni syndromelung adenocarcinomanext-generation sequencingTP53 temperature-sensitive mutation

Identifiers

PMID33194065
PMCPMC7653629
OpenAlexW3103299299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.